OnKure Therapeutics (OKUR) grants director Valerie Jansen 22,350 stock options

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. reported that director Valerie Malyvanh Jansen received a grant of a stock option covering 22,350 shares of Class A common stock. The option has an exercise price of $4.14 per share and expires on August 6, 2036. According to the terms, 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders, conditioned on her continued service as a provider through the applicable vesting date. Following this award, she holds 22,350 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jansen Valerie Malyvanh

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	22,350	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,350 shares (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Key Figures

Options granted: 22,350 shares Exercise price: $4.14 per share Expiration date: August 6, 2036 +2 more

5 metrics

Options granted 22,350 shares Stock option grant to director Valerie Malyvanh Jansen

Exercise price $4.14 per share Exercise price of the stock option covering 22,350 shares

Expiration date August 6, 2036 Expiration of the granted stock option

Vesting date reference June 4, 2027 100% vests on earlier of June 4, 2027 or day prior to next annual meeting

Holdings after grant 22,350 options Total stock options held directly by the director after the transaction

Key Terms

Stock Option, exercise price, vesting, expiration date

4 terms

Stock Option financial

"reported that director Valerie Malyvanh Jansen received a grant of a stock option covering"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The option has an exercise price of $4.14 per share and expires"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100% of the shares subject to the option will vest on the earlier of June 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"The option has an exercise price of $4.14 per share and expires on August 6, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

What stock option grant did OnKure Therapeutics (OKUR) report for Valerie Malyvanh Jansen?

OnKure Therapeutics reported a stock option grant for 22,350 shares of Class A common stock to director Valerie Malyvanh Jansen, with an exercise price of $4.14 per share and expiration on August 6, 2036.

What is the vesting schedule of the new stock options reported by OKUR?

The option vests 100% on the earlier of June 4, 2027 or the day before OnKure’s next annual stockholder meeting, subject to continued service by Valerie Malyvanh Jansen through the applicable vesting date.

What is the exercise price of Valerie Malyvanh Jansen’s new options at OnKure Therapeutics (OKUR)?

The reported stock option grant has an exercise price of $4.14 per share for 22,350 underlying shares of Class A common stock, giving the director the right to buy those shares at that price once vested.

How many OnKure Therapeutics (OKUR) options does Valerie Malyvanh Jansen hold after this transaction?

After the reported grant, Valerie Malyvanh Jansen directly holds 22,350 stock options in OnKure Therapeutics, all relating to Class A common stock as disclosed in the Form 4 filing.

When do the newly granted OnKure Therapeutics (OKUR) options expire?

The stock options granted to Valerie Malyvanh Jansen are scheduled to expire on August 6, 2036, providing a long-dated right to purchase 22,350 shares at the fixed exercise price of $4.14 per share once vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 04:38 PM Accepted by SEC EDGAR 08/11/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jansen Valerie Malyvanh

(Last) (First) (Middle)

C/O ONKURE THERAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.14	08/07/2026		A		22,350		(1)	08/06/2036	Class A Common Stock	22,350	$0	22,350	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Rogan Nunn, by power of attorney	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)